Long-term outcome in Danish real-life patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors

Autor: Bjornhart, B., Mouritzen, M., Kristiansen, C., Holmskov, K. H., Wedervang, K., Jorgensen, T. L., Herrstedt, J., Pohl, M., Schytte, T.

Publikováno v: Bjornhart, B, Mouritzen, M, Kristiansen, C, Holmskov, K H, Wedervang, K, Jorgensen, T L, Herrstedt, J, Pohl, M & Schytte, T 2022, ' Long-term outcome in Danish real-life patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors ', Annals of Oncology, vol. 33, no. Suppl. 7, 1114P, pp. S1060 . https://doi.org/10.1016/j.annonc.2022.07.1239

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5efebd677904584acfb7e60d015ad198
https://vbn.aau.dk/da/publications/b90fc9e0-5c45-4730-9d63-49ba01c7d8c2

Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort

Autor: Mouritzen, M., Bjoernhart, B., Poehl, M., Ladekarl, M., Vesteghem, C., Boegsted, M., Nielsen, A.W. Moelby, Meldgaard, P., Hansen, K.H., Larsen, J.W.W., Kristiansen, C., Wedervang, K., Bareid-Oestby, A-C., Frank, M.S., Persson, G., Kristensen, E.B., Homann, P.H., Carus, A.

Publikováno v: Mouritzen, M, Bjoernhart, B, Poehl, M, Ladekarl, M, Vesteghem, C, Boegsted, M, Nielsen, A W M, Meldgaard, P, Hansen, K H, Larsen, J W W, Kristiansen, C, Wedervang, K, Bareid-Oestby, A-C, Frank, M S, Persson, G, Kristensen, E B, Homann, P H & Carus, A 2020, ' Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort ', Annals of Oncology, vol. 31, no. Suppl. 4, 1334P, pp. S858 . https://doi.org/10.1016/j.annonc.2020.08.1648
Mouritzen, M, Bjørnhart, B, Pøhl, M, Ladekarl, M, Vesteghem, C, Bøgsted, M, Moelby Nielsen, A W, Meldgaard, P, Holmskov Hansen, K, Larsen, J W W, Kristiansen, C, Wedervang, K, Bareid-Oestby, A C, Frank, M S, Persson, G, Kirstensen, E B, Hormann, P H & Carus, A 2020, ' Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort ', Annals of Oncology, vol. 31, no. Suppl. 4, 1334P . https://doi.org/10.1016/j.annonc.2020.08.1648

BackgroundImmune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced non-small cell lung cancer (NSCLC). In the pivotal Keynote-024 study with highly selected patients, pembrolizumab improved survival compared with pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::10fd688e5f4f8ff43273a84d0cb636f6
https://vbn.aau.dk/da/publications/4c9dbe1d-68f1-4c67-bb9c-af0e8f9ea219

1114P Long-term outcome in Danish real-life patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors

Autor: Bjornhart, B., Mouritzen, M., Kristiansen, C., Holmskov, K.H., Wedervang, K., Jorgensen, T.L., Herrstedt, J., Pohl, M., Schytte, T.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1060-S1060

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.